Article Per Year (5 Year)
p-Index From 2020 - 2025
1.116
P-Index
This Author published in this journals
All Journal Community Development Journal: Jurnal Pengabdian Masyarakat Narra J Indonesian Basic and Experimental Health Sciences
Sunarso, Indrayana
Unknown Affiliation
Humanities Biochemistry, Genetics & Molecular Biology Economics, Econometrics & Finance Education Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
AKTIVITAS FISIK DAN AKTIVASI RUMAH SINGGAH MENINGKATKAN KUALITAS HIDUP PASIEN LUPUS Nurudhin, Arief; Werdiningsih, Yulyani; Prabowo, Nurhasan Agung; Sunarso, Indrayana
Community Development Journal : Jurnal Pengabdian Masyarakat Vol. 4 No. 6 (2023): Volume 4 Nomor 6 Tahun 2023
Publisher : Universitas Pahlawan Tuanku Tambusai

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31004/cdj.v4i6.23378

Abstract

Penyakit Lupus Eritematosus Sistemik (LES) merupakan suatu penyakit autoimun yang bersifat kronis dan menyebabkan nyeri pada semua ODAPUS (Orang dengan Lupus). Intervensi psikososial bertujuan untuk mengurangi rasa sakit serta meningkatkan kualitas hidup para ODAPUS. Nyeri dipengarui olehberbagai faktro salah satunya adalah faktor psikologis. Hasil analisis situasi menunjukkan bahwa nyeri menjadi masalah utama yang sering dialami oleh ODAPUS, meskipun mereka sudah rutin minum obat. Oleh karena itu, diperlukan pendekatan lain untuk mengurangi nyeri ini. Pengabdian kepada masyarakat ini bertujuan untuk meningkakan kualitas hidup pasien lupus melalui pendekatan edukasi yang berbasis komunitas.Metode pelaksanaan pengabdian ini menggunakan ceramah, diskusi, Outbond dan perbaikan rumah singgahpada ODAPUS yang merupakan anggota Yayasan Tittari. Kegiatan pengabdian dilaksanakan di Rumah Singgah Yayasan Tittari dan juga Area Danau UNS. Materi yang diangkat dalam pengabdian ini mencakup pengetahuan tentang nyeri bagi ODAPUS, metode sederhana untuk mengurangi tingkat nyeri, serta pentingnya memahami peran depresi, stres, dan ansietas dalam menyebabkan nyeri. Serta Perbaikan rumah singgah yang mengalami kerusakan selama pandemi COVID 19. Diharapkan melalui pendekatan eduksi dan perbaikan sarana rumah singgah dapat memperbaiki kualitas hidup pasien Lupus.Pemateri pada kegiatan ini adalah seorang dokter ahli nyeri rematologi. Jumlah peserta ODAPUS yang mengikuti kegiatan ini berjumlah 70 orang. Evaluasi hasil kegiatan dilakukan dengan membandingkan skor Lupus QOL Sebelum dan dalam rentang 2 bulan sesudah kegiatan. Kuisioner diedarkan secara online melaui GForm. Hasil mengabdian didapatkan adanya peningkatan Skor LupusQoL dalam beberbagai domain, serta signifikan secara statistik. .Hal ini menunjukkan adanya edukasi berbasis kominitas dan perbaikan sarana rumah singgah memperbaiki kualitas hidup ODAPUS yang terlibat kegiatan tersebut.
Umbilical cord mesenchymal stem cell-derived secretome as a potential treatment for systemic lupus erythematosus: A double-blind randomized controlled trial Nurudhin, Arief; Werdiningsih, Yulyani; Sunarso, Indrayana; Marwanta, Sri; Damayani, Aritantri; Prabowo, Nurhasan A.; Affandi, Andri; Gazali, Itqan; Safitri, Ayu SI.; Sidarta, Brigitte RA.
Narra J Vol. 5 No. 1 (2025): April 2025
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v5i1.1799

Abstract

Umbilical cord mesenchymal stem cell-derived (UCMSC-derived) secretome is anti-apoptotic, anti-inflammatory, antifibrotic, angiogenic, and tissue-regenerating. Thus, it may treat systemic lupus erythematosus (SLE). The aim of this study was to investigate the impact of the UCMSC-derived secretome on SLE patients' disease activity, using Mexican systemic lupus erythematosus disease activity index (MEX-SLEDAI) score, complement (C3 and C4) levels, tumor necrosis factor-alpha (TNF-α), anti-double-stranded DNA (anti-dsDNA), and interleukin-6 (IL-6) levels. This double-blind randomized controlled trial investigated the efficacy and safety of UCMSC-derived secretome in SLE patients with moderate disease activity. A total of 29 female patients were randomized into two groups to receive weekly 1.5 cc intramuscular injections of UCMSC-derived secretome or placebo (0.9% NaCl) for six weeks. Disease activity was assessed using the MEX-SLEDAI score, C3 and C4 levels, pro-inflammatory cytokines (IL-6 and TNF-α), and anti-dsDNA antibodies at baseline, Day 22, and Day 43. Results showed a significant reduction in MEX-SLEDAI scores in the secretome group compared to the placebo group (p<0.05). Complement C3 levels significantly increased in the secretome group on Day 43, indicating improved immune homeostasis, while C4 levels did not show significant differences between groups. IL-6 and TNF-α levels showed decreasing trends in the secretome group. Anti-dsDNA levels exhibited a decreasing trend in the secretome group, though not statistically significant. Importantly, no severe adverse events were observed, underscoring the safety of the intervention. UCMSC-derived secretome demonstrated immunomodulatory and anti-inflammatory effects, reducing disease activity in SLE patients. These findings suggest its potential as a safe and effective adjunct therapy for SLE, although further studies with larger sample sizes and extended follow-up periods are needed to validate these results.
Mesenchymal Stem Cell Secretome Improves Bone Quality in Autoimmune Rheumatic Patients (AIIRD): A Case Report Werdiningsih, Yulyani; Nurudhin, Arief; sunarso, indrayana
Indonesian Basic and Experimental Health Sciences Vol. 13 No. 1 (2024): November
Publisher : Rumah Sakit Umum Daerah Dr. Moewardi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11594/ibehs.vol13iss1pp11-15

Abstract

ABSTRAK Autoimmune Inflammatory Rheumatic Disease (AIIRD) is a group of different disorders, which have similar clinical, laboratory and immunological manifestations. In East Asia, the top 3 diseases included in AIIRD are Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Sjogren's Syndrome. Glucocorticoids are still one of the therapeutic modalities for AIIIRD with their antiinflammatory and immunosuppressive effects. However, glucocorticoids have some side effects. One side effect of concern is decreased bone density. The condition of glucocorticoid induced osteoporosis (GIOP) is reported with increasing prevalence. The main effect of the use of glucocorticoids on bones is the presence of impaired bone formation regardless of the role of inflammation.  Secretome stem cells contain bioactives that exhibit diverse physiological functions such as immunomodulation, anti-inflammatory, angiogenesis, anti-apoptotic and anti-oxidation. Secretome can modulate cell differentiation by promoting osteogenesis and inhibiting adipogenesis. In this case report, it showed improvements in markers of bone damage, inflamation, and vitamin D levels after stem cell secretome administration in AIIRD patients with long-term corticosteroid use.
Effect of the Period of Glucocorticoid Administration on Bone Quality in Patients with Autoimmune Inflammatory Rheumatism Disease (AIIRD) Werdiningsih, Yulyani; Sunarso, indrayana; Nurudhin, Arief
Indonesian Basic and Experimental Health Sciences Vol. 13 No. 2 (2025): APRIL
Publisher : Rumah Sakit Umum Daerah Dr. Moewardi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.11594/ibehs.vol13iss2pp52-58

Abstract

Introduction Inflammatory autoimmune rheumatic disease (AIIRD) such as rheumatoid arthritis, systemic lupus erythematosus, and Sjogren's syndrome often requires long-term glucocorticoid therapy. Despite its effectiveness, glucocorticoids are recognized to cause decreased bone quality and increase the risk of osteoporosis. This study aims to evaluate the effect of the period of glucocorticoid administration on bone quality parameters in AIIRD patients. Methods This study was an observational analytical study with a cross-sectional design. A total of 28 female patients with AIIRD were divided into two groups based on the period of glucocorticoid administration: less than 24 months and more than 24 months. The parameters to be measured included bone mineral density (BMD), Collagen Type I C-Telopeptide (CTX), Vitamin D3 levels, and Calcium Ions. Data analysis was conducted using the Mann-Whitney test and the unpaired t-test with a significance level of p<0.05. Results There was no statistically significant difference between the two groups on all measured parameters. The mean BMD in the group of less than 24 months was 0.9471 kg/m², while in the group of more than 24 months it was 0.8920 kg/m² (p>0.05). The mean CTX also did not differ significantly between the two groups (0.2474 vs. 0.2508 ng/mL; p>0.05). Vitamin D3 and Calcium Ion levels showed similar results in the absence of significant differences (Vitamin D3: 15,596 vs. 16,255 ng/mL; Calcium Ion: 1,075 vs. 1,040 mmol/L; p>0.05). Conclusions The period of glucocorticoid administration does not show a significant effect on bone quality in AIIRD patients in this study. Nonetheless, regular monitoring and an individualized approach are still necessary to prevent bone complications in patients receiving long-term glucocorticoid therapy.
Co-Authors Affandi, Andri Arief Nurudhin Damayani, Aritantri Gazali, Itqan Marwanta, Sri Prabowo, Nurhasan A. Prabowo, Nurhasan Agung Safitri, Ayu SI. Sidarta, Brigitte RA. Werdiningsih, Yulyani